Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar-Apr;50(2):115–125. doi: 10.1590/0100-3984.2015.0140

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Small HCC diagnosed using gadoxetate disodium (hepatobiliary contrast agent). Axial fat-suppressed (A) SS-FSE T2-WI, axial pre- (B) and postgadolinium (gadoxetate disodium) fat-suppressed 3D-GRE T1-WI in the arterial (C), interstitial (D) and hepatobiliary phases (E). A small HCC is depicted in the right liver lobe, medial to the right hepatic vein, showing isointensity on T2-WI, mild low signal intensity on T1-WI, arterial hyper-enhancement (C) and no perceptible washout on the delayed phase (D). On the hepatobiliary phase, due to the presence of impaired hepatocytes, the HCC shows no enhancement (arrow, E). This case exemplifies the advantages of hepatobiliary contrast agents in the characterization of liver nodules in the setting of cirrhosis.